Your browser is no longer supported. Please, upgrade your browser.
Settings
BPTH Bio-Path Holdings, Inc. daily Stock Chart
BPTH [NASD]
Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-0.06 Insider Own0.20% Shs Outstand99.21M Perf Week-7.90%
Market Cap36.92M Forward P/E- EPS next Y-0.02 Insider Trans0.00% Shs Float87.94M Perf Month-5.22%
Income-5.30M PEG- EPS next Q-0.02 Inst Own19.20% Short Float3.12% Perf Quarter-46.84%
Sales0.01M P/S2839.70 EPS this Y-19.60% Inst Trans0.06% Short Ratio4.43 Perf Half Y-61.43%
Book/sh0.08 P/B4.65 EPS next Y71.40% ROA-49.20% Target Price3.25 Perf Year-77.98%
Cash/sh0.07 P/C5.20 EPS next 5Y- ROE-65.90% 52W Range0.33 - 1.75 Perf YTD-72.44%
Dividend- P/FCF- EPS past 5Y-10.70% ROI- 52W High-78.74% Beta3.03
Dividend %- Quick Ratio11.80 Sales past 5Y- Gross Margin- 52W Low12.66% ATR0.03
Employees12 Current Ratio11.80 Sales Q/Q- Oper. Margin- RSI (14)45.23 Volatility8.56% 9.30%
OptionableNo Debt/Eq0.00 EPS Q/Q80.00% Profit Margin- Rel Volume0.29 Prev Close0.36
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume619.80K Price0.37
Recom2.00 SMA20-4.07% SMA50-7.50% SMA200-55.35% Volume180,793 Change2.09%
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Jul-17-17 08:00AM  Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors GlobeNewswire
Jun-29-17 04:30PM  Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) Accesswire
May-11-17 09:01AM  Bio-Path reports 1Q loss Associated Press -8.49%
07:00AM  Bio-Path Holdings Reports First Quarter 2017 Financial Results GlobeNewswire
May-04-17 08:00AM  Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017 GlobeNewswire
Apr-17-17 08:45AM  Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher Zacks +13.80%
08:00AM  Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development GlobeNewswire
Apr-05-17 08:01AM  Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma GlobeNewswire -9.52%
08:01AM  Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma
Mar-21-17 01:04PM  BIO-PATH HOLDINGS INC Financials -6.62%
Mar-15-17 08:30AM  Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today -11.75%
07:36AM  Bio-Path reports 4Q loss Associated Press
07:36AM  Bio-Path reports 4Q loss
07:11AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
07:04AM  BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
07:00AM  Bio-Path Holdings Reports Full Year 2016 Financial Results GlobeNewswire
Mar-14-17 08:00AM  Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-13-17 08:00AM  Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 GlobeNewswire +6.81%
Mar-10-17 03:38PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +8.12%
08:00AM  Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting GlobeNewswire
Mar-09-17 04:01PM  Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 GlobeNewswire +12.51%
Mar-08-17 04:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
Feb-21-17 04:31PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board GlobeNewswire
Feb-08-17 03:24PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-07-17 08:00AM  Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Dec-16-16 12:22PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
Dec-15-16 09:03PM  How Noodles & Co (NDLS) Stacks Up Against Its Peers Insider Monkey
09:03PM  How Noodles & Co (NDLS) Stacks Up Against Its Peers at Insider Monkey
Dec-06-16 01:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:00AM  Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-16 08:40AM  Bio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-10-16 07:11AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:00AM  Bio-Path Holdings Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-09-16 04:50PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report +10.00%
Nov-04-16 04:01PM  Bio-Path Holdings to Announce Third Quarter 2016 Financial Results on November 10, 2016 GlobeNewswire
01:42PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting GlobeNewswire
Nov-03-16 08:00AM  Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire +5.62%
Nov-02-16 08:00AM  Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia GlobeNewswire
Sep-07-16 12:36PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-06-16 08:00AM  Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Aug-10-16 08:01AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:30AM  Bio-Path Holdings Reports Second Quarter 2016 Financial Results GlobeNewswire
06:38AM  Bio-Path reports 2Q loss
Aug-09-16 04:19PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report
Aug-03-16 08:00AM  Bio-Path Holdings to Announce Second Quarter 2016 Financial Results on August 10, 2016 GlobeNewswire
Aug-01-16 04:37PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exh
Jul-06-16 12:52PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
08:00AM  Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference GlobeNewswire
Jul-01-16 06:05AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jun-30-16 06:10AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
Jun-29-16 11:59AM  Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering GlobeNewswire -10.05%
Jun-28-16 08:00AM  Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer GlobeNewswire
Jun-20-16 04:01PM  Bio-Path Holdings to Join Russell 3000® and Global Indexes GlobeNewswire
Jun-06-16 02:27PM  Bio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
12:41PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
09:00AM  Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 GlobeNewswire
May-20-16 02:51PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure
May-19-16 07:30AM  Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-11-16 08:30AM  Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
07:46AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:39AM  Bio-Path reports 1Q loss
07:30AM  Bio-Path Holdings Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Bio Path Holdings Inc Earnings Release - Time Not Supplied
May-10-16 05:22PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report
09:45AM  Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
May-05-16 03:45PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.18%
08:00AM  Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference GlobeNewswire
May-04-16 08:00AM  Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016 GlobeNewswire
Apr-18-16 07:17AM  Coverage initiated on Bio-Path by Rodman & Renshaw
Apr-05-16 10:45AM  Stocks to Buy: Many Have Chosen These Today April 5th Accesswire -6.46%
Mar-24-16 02:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-23-16 08:55AM  Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center Business Wire
Mar-16-16 12:01PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition
09:09AM  Bio-Path reports 4Q loss
08:55AM  Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results Business Wire
Mar-15-16 04:30PM  BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
Mar-08-16 12:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution Business Wire
Mar-07-16 05:16PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure +6.92%
08:55AM  Bio-Path Holdings to Present at the 28th Annual ROTH Conference Business Wire
Mar-04-16 12:09PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure -14.05%
Mar-03-16 08:55AM  Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia Business Wire
Feb-01-16 01:59PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference Business Wire
Jan-13-16 05:26PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-16 02:40PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:55AM  Bio-Path Holdings to Present at Biotech Showcase 2016 Business Wire
Dec-30-15 02:11PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
Dec-08-15 02:51PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -7.54%
08:55AM  Bio-Path Holdings Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-10-15 04:26PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
09:03AM  Bio-Path reports 3Q loss
08:55AM  Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results Business Wire
Nov-09-15 04:21PM  BIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report +5.59%
Nov-05-15 01:02PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:27AM  Bio-Path Holdings Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting Business Wire
Oct-14-15 03:50PM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-13-15 04:05PM  Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum Business Wire
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.